Tirzepatide Once Weekly for the Treatment of Obesity

Autor: Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa Connery, Breno Alves, Arihiro Kiyosue, Shuyu Zhang, Bing Liu, Mathijs C. Bunck, Adam Stefanski

Publikováno v: New England Journal of Medicine. 387:205-216

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55c0c48c6591573a4fa9c42fafcbe09a
https://doi.org/10.1056/nejmoa2206038

0572 Weight reduction and the impact on apnea-hypopnea index: a meta-analysis

Autor: Atul Malhotra, Alexandra Curtis, Julia Dunn, Mathijs C Bunck, Josef Bednarik

Publikováno v: SLEEP. 46:A251-A252

Introduction The occurrence of obstructive sleep apnea (OSA) is strongly associated with obesity. Behavioral, pharmacological, and surgical interventions that promote weight reduction can reduce OSA severity and improve other common obesity related c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::338a321af2398616a43bc93a8218b432
https://doi.org/10.1093/sleep/zsad077.0572

1164-P: The Prevalence of Comorbidities among People with Obesity with and without Prediabetes

Autor: JANET FORD, MAUREEN J. LAGE, KRISTINA BOYE, JAY P. BAE, KENDRA A. TERRELL, MATHIJS C. BUNCK

Publikováno v: Diabetes. 71

Objective: Obesity and prediabetes are widespread in the U.S., with an estimated 42% of adults living with obesity and 35% living with prediabetes. This research examines the prevalence of comorbidities among people with obesity with or without predi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f2a8727fdf472a6e19d0dc1bfe345792
https://doi.org/10.2337/db22-1164-p

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus : A post-hoc analysis of a 52-week randomised trial

Autor: Marcel H.A. Muskiet, Jaap A. Joles, Lennart Tonneijck, Robert J. Heine, D.H. van Raalte, Björn Eliasson, A. Cornér, Mathijs C. Bunck, M. Diamant, Hannele Yki-Järvinen

Publikováno v: Muskiet, M H A, Bunck, M C, Heine, R J, Cornér, A, Yki-Järvinen, H, Eliasson, B, Joles, J A, Diamant, M, Tonneijck, L & van Raalte, D H 2019, ' Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial ', Diabetes Research and Clinical Practice, vol. 153, pp. 14-22 . https://doi.org/10.1016/j.diabres.2019.05.001
Diabetes Research and Clinical Practice, 153, 14-22. Elsevier Ireland Ltd

Aims: To compare the effects of long-term treatment with the GLP-1RA exenatide twicedaily versus titrated insulin glargine (iGlar) on renal function and albuminuria in type 2 diabetes (T2DM) patients. Methods: We post-hoc evaluated renal outcome-data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f6361a93d24144c6f7106649afcac8
http://hdl.handle.net/10138/315644

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels

Autor: Mark M. Smits, Björn Eliasson, Anja Cornér, Robert J. Heine, Ulf Smith, Daniël H. van Raalte, Hannele Yki-Järvinen, Mathijs C. Bunck, Michaela Diamant

Publikováno v: Smits, M M, Bunck, M C, Diamant, M, Corner, A, Eliasson, B, Heine, R J, Smith, U, Yki-Jarvinen, H & van Raalte, D H 2016, ' Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels ', Diabetes Care, vol. 39, no. 3, pp. E42-E43 . https://doi.org/10.2337/dc15-2489
Diabetes Care, 39(3), E42-E43. American Diabetes Association Inc.

α-Cell dysfunction contributes to hyperglycemia in type 2 diabetes and is characterized by inappropriately increased basal and postprandial glucagon levels (1). The regulation of glucagon secretion remains poorly understood. Glucagon-like peptide 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a320a9d6077f0ec822b7f5ab49a991be
https://research.vumc.nl/en/publications/895ba4b1-c795-4ed1-912c-3b0a313b2fb8